Quarterly report pursuant to Section 13 or 15(d)

Basis of Presentation and Significant Accounting Policies (Details Narrative)

v3.4.0.3
Basis of Presentation and Significant Accounting Policies (Details Narrative)
3 Months Ended
Apr. 08, 2015
USD ($)
Mar. 09, 2015
USD ($)
Mar. 31, 2016
USD ($)
Breathlyzers
shares
Mar. 31, 2015
USD ($)
shares
Dec. 31, 2015
USD ($)
Allowance for doubtful accounts receivable     $ 864,000   $ 864,000
Allowances charged for doubtful accounts      
Concentration risk percentage     10.00%    
Investment in Hainan Savy Akers Biosciences, Ltd. joint venture $ 64,091 $ 64,675      
Percentage of ownership in Hainan Savy Akers Biosciences, Ltd. joint venture     19.90%    
Deferred revenue     $ 99,968    
Shipping, handling and transportation costs     16,045 $ 18,941  
Cost of net revenue     21,714 44,690  
Net Loss Attributable to Common Stockholders     $ 1,508,929 $ 1,321,799  
Options [Member]          
Antidilutive securities excluded from computation of earnings per share | shares     220,500 175,000  
Trade Receivable [Member]          
Concentration risk percentage     74.00%    
Concentration risk, number of customer | Breathlyzers     2    
Percentage of customer accounted for trade receivables     30.00%    
Fulton Bank of New Jersey [Member]          
Cash     $ 161,429   369,525
Bank of America [Member]          
Cash     14,921   28,494
PayPal [Member]          
Cash     $ 4,040   $ 4,040
Minimum [Member]          
Normal credit terms extended to customers     30 days    
Maximum [Member]          
Normal credit terms extended to customers     90 days    
Cash, FDIC insured amount     $ 250,000    
Maximum [Member] | Patents [Member]          
Finite-lived intangible asset, useful life     17 years